Toshiro Okazaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Toshiro Okazaki has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Makoto Taniguchi
Department of Life Science, Medical Research Institute, Kanazawa Medical University, Uchinada, Japan
11 shared publications - Kazuyuki Kitatani
Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, Japan
7 shared publications - Hisanori Umehara
Northern County Center for RA and Autoimmune Disease, Hayashi Hospital, Fukui, Japan
5 shared publications Yasuyuki Igarashi
The ‖‖Laboratory of Biomembrane and Biofunctional Chemistry, Faculty of Advanced Life Sciences, Hokkaido University, Kita 21-jo, Nishi 11-choume, Kita-ku, Sapporo 001-0021, Japan
5 shared publicationsAkio Nakajima
4 shared publicationsHaruka Iwao
4 shared publications
Latest Publications
- 1 August 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1863 (8) , 928-938
Tissue-selective alteration of ethanolamine plasmalogen metabolism in dedifferentiated colon mucosa
- 1 August 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1863 (8) , 928-938
Tissue-selective alteration of ethanolamine plasmalogen metabolism in dedifferentiated colon mucosa
- Open Access
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (9) , 3816-3830
Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer
Sphingomyelin synthase 2 (SMS2) is the synthetic enzyme of sphingomyelin (SM), which regulates membrane fluidity and microdomain structure. SMS2 plays a role in LPS‐induced lung injury and inflammation; however, its role in inflammation‐mediated tumorigenesis is unclear. We investigated the effect of SMS2 deficiency on dextran sodium sulfate (DSS)–induced murine colitis and found inhibition of DSS‐induced inflammation in SMS2‐deficient (SMS2 −/− ) mice. DSS treatment induced a significant increase in ceramide levels, with a decrease of SM levels in SMS2 −/− colon tissue, and demonstrated attenuation of the elevation of both inflammation‐related gene expression and proinflammatory cytokines and chemokines, leukocyte infiltration, and MAPK and signal transducer and activator of transcription 3 activation. After undergoing transplantation of wild‐type bone marrow, SMS2 −/− mice also exhibited inhibition of DSS‐induced inflammation in the colon, which suggested that SMS2 deficiency in bone marrow–derived immune cells was not involved in the inhibition of colitis. Finally, in an azoxymethane/DSS‐induced cancer model, SMS2 deficiency significantly decreased tumor incidence in the colon. Our results demonstrate that SMS2 deficiency inhibits DSS‐induced colitis and subsequent colitis‐associated colon cancer via inhibition of colon epithelial cell–mediated inflammation; therefore, inhibition of SMS2 may be a potential therapeutic target for human colitis and colorectal cancer.—Ohnishi, T., Hashizume, C., Taniguchi, M., Furumoto, H., Han, J., Gao, R., Kinami, S., Kosaka, T., Okazaki, T. Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer. FASEB J. 31, 3816–3830 (2017). www.fasebj.org —Ohnishi, Toshio, Hashizume, Chieko, Taniguchi, Makoto, Furumoto, Hidehiro, Han, Jia, Gao, Rongfen, Kinami, Shinichi, Kosaka, Takeo, Okazaki, Toshiro Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer. FASEB J. 31, 3816–3830 (2017)
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (9) , 3816-3830
Open AccessSphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer
Sphingomyelin synthase 2 (SMS2) is the synthetic enzyme of sphingomyelin (SM), which regulates membrane fluidity and microdomain structure. SMS2 plays a role in LPS‐induced lung injury and inflammation; however, its role in inflammation‐mediated tumorigenesis is unclear. We investigated the effect of SMS2 deficiency on dextran sodium sulfate (DSS)–induced murine colitis and found inhibition of DSS‐induced inflammation in SMS2‐deficient (SMS2 −/− ) mice. DSS treatment induced a significant increase in ceramide levels, with a decrease of SM levels in SMS2 −/− colon tissue, and demonstrated attenuation of the elevation of both inflammation‐related gene expression and proinflammatory cytokines and chemokines, leukocyte infiltration, and MAPK and signal transducer and activator of transcription 3 activation. After undergoing transplantation of wild‐type bone marrow, SMS2 −/− mice also exhibited inhibition of DSS‐induced inflammation in the colon, which suggested that SMS2 deficiency in bone marrow–derived immune cells was not involved in the inhibition of colitis. Finally, in an azoxymethane/DSS‐induced cancer model, SMS2 deficiency significantly decreased tumor incidence in the colon. Our results demonstrate that SMS2 deficiency inhibits DSS‐induced colitis and subsequent colitis‐associated colon cancer via inhibition of colon epithelial cell–mediated inflammation; therefore, inhibition of SMS2 may be a potential therapeutic target for human colitis and colorectal cancer.—Ohnishi, T., Hashizume, C., Taniguchi, M., Furumoto, H., Han, J., Gao, R., Kinami, S., Kosaka, T., Okazaki, T. Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer. FASEB J. 31, 3816–3830 (2017). www.fasebj.org —Ohnishi, Toshio, Hashizume, Chieko, Taniguchi, Makoto, Furumoto, Hidehiro, Han, Jia, Gao, Rongfen, Kinami, Shinichi, Kosaka, Takeo, Okazaki, Toshiro Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis‐associated colon cancer. FASEB J. 31, 3816–3830 (2017)
- 1 December 2015
- Vol. 87 (6) , 789-94
[Quantitative analysis of lipids constructing plasma membrane microdomains by LC-MS].
- 1 December 2015
- Vol. 87 (6) , 789-94
[Quantitative analysis of lipids constructing plasma membrane microdomains by LC-MS].
- Open Access
- 1 August 2015
- Published by Elsevier in Journal of Lipid Research
- Vol. 56 (8) , 1594-1605
Analysis of lipid-composition changes in plasma membrane microdomains
- 1 August 2015
- Published by Elsevier in Journal of Lipid Research
- Vol. 56 (8) , 1594-1605
Open AccessAnalysis of lipid-composition changes in plasma membrane microdomains
- Open Access
- 1 June 2015
- Published by Elsevier in Molecules and Cells
- Vol. 38 (6) , 482-495
Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies
Kazuyuki Kitatani, Makoto Taniguchi, and Toshiro Okazaki. Mol. Cells 2015;38:482-95. https://doi.org/10.14348/molcells.2015.0118
- 1 June 2015
- Published by Elsevier in Molecules and Cells
- Vol. 38 (6) , 482-495
Open AccessRole of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies
Kazuyuki Kitatani, Makoto Taniguchi, and Toshiro Okazaki. Mol. Cells 2015;38:482-95. https://doi.org/10.14348/molcells.2015.0118
- Open Access
- 9 April 2015
- Published by Springer Nature in Cell Death & Disease
- Vol. 6 (4) , e1717
Lysosomal ceramide generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis
We previously reported that IL-2 deprivation induced acid sphingomyelinase-mediated (ASM-mediated) ceramide elevation and apoptosis in an NK/T lymphoma cell line KHYG-1. However, the molecular mechanism of ASM–ceramide-mediated apoptosis during IL-2 deprivation is poorly understood. Here, we showed that IL-2 deprivation induces caspase-dependent apoptosis characterized by phosphatidylserine externalization, caspase-8, -9, and -3 cleavage, and degradation of X-linked inhibitor of apoptosis protein (XIAP). IL-2 re-supplementation rescued apoptosis via inhibition of XIAP degradation without affecting caspase cleavage. However, IL-2 deprivation induced ceramide elevation via ASM in lysosomes and activated lysosomal cathepsin B (CTSB) but not cathepsin D. A CTSB inhibitor CA-074 Me and knockdown of CTSB inhibited ceramide-mediated XIAP degradation and apoptosis. Inhibition of ceramide accumulation in lysosomes using an ASM inhibitor, desipramine, decreased cytosolic activation of CTSB by inhibiting its transfer into cytosol from the lysosome. Knockdown of ASM also inhibited XIAP degradation and apoptosis. Furthermore, cell permeable N-acetyl sphingosine (C2-ceramide), which increases mainly endogenous d18:1/16:0 and d18:1/24:1 ceramide-like IL-2 deprivation, induced caspase-dependent apoptosis with XIAP degradation through CTSB. These findings suggest that lysosomal ceramide produced by ASM mediates XIAP degradation by activation of cytosolic CTSB and caspase-dependent apoptosis. The ASM–ceramide–CTSB signaling axis is a novel pathway of ceramide-mediated apoptosis in IL-2-deprived NK/T lymphoma cells.
- 9 April 2015
- Published by Springer Nature in Cell Death & Disease
- Vol. 6 (4) , e1717
Open AccessLysosomal ceramide generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis
We previously reported that IL-2 deprivation induced acid sphingomyelinase-mediated (ASM-mediated) ceramide elevation and apoptosis in an NK/T lymphoma cell line KHYG-1. However, the molecular mechanism of ASM–ceramide-mediated apoptosis during IL-2 deprivation is poorly understood. Here, we showed that IL-2 deprivation induces caspase-dependent apoptosis characterized by phosphatidylserine externalization, caspase-8, -9, and -3 cleavage, and degradation of X-linked inhibitor of apoptosis protein (XIAP). IL-2 re-supplementation rescued apoptosis via inhibition of XIAP degradation without affecting caspase cleavage. However, IL-2 deprivation induced ceramide elevation via ASM in lysosomes and activated lysosomal cathepsin B (CTSB) but not cathepsin D. A CTSB inhibitor CA-074 Me and knockdown of CTSB inhibited ceramide-mediated XIAP degradation and apoptosis. Inhibition of ceramide accumulation in lysosomes using an ASM inhibitor, desipramine, decreased cytosolic activation of CTSB by inhibiting its transfer into cytosol from the lysosome. Knockdown of ASM also inhibited XIAP degradation and apoptosis. Furthermore, cell permeable N-acetyl sphingosine (C2-ceramide), which increases mainly endogenous d18:1/16:0 and d18:1/24:1 ceramide-like IL-2 deprivation, induced caspase-dependent apoptosis with XIAP degradation through CTSB. These findings suggest that lysosomal ceramide produced by ASM mediates XIAP degradation by activation of cytosolic CTSB and caspase-dependent apoptosis. The ASM–ceramide–CTSB signaling axis is a novel pathway of ceramide-mediated apoptosis in IL-2-deprived NK/T lymphoma cells.
- 1 January 2015
- Published by Springer Nature
- p. 23-51
Role of Sphingolipids in Hematological Malignancies: Lymphoproliferative Disorders
- 1 January 2015
- Published by Springer Nature
- p. 23-51
Role of Sphingolipids in Hematological Malignancies: Lymphoproliferative Disorders
- 1 August 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (3) , 438-446
Dietary glucosylceramides suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by the inhibition of angiogenesis through an increase in ceramide
We previously reported that dietary glucosylceramides show cancer-prevention activity in a mouse xenograft model of human head and neck cancer cells (SCCKN). However, the mechanism was unclear. Ceramides, metabolites of glucosylceramides, induce apoptotic cell death in various malignancies. Here, we investigated the inhibitory effects of dietary glucosylceramides on tumor growth in vivo and in vitro. SCCKN were subcutaneously inoculated into the right flanks of NOD/SCID mice. Mice were treated with or without dietary glucosylceramides (300 mg/kg) daily for 14 consecutive days after confirmation of tumor progression. Microvessel areas around the tumor were assessed by hematoxylin–eosin staining and immunohistochemistry of CD31, and, as markers for angiogenesis, protein levels of VEGF, VEGF receptor-2, and HIF-1α were assessed by Western blotting. Mass spectrometry was performed to measure the levels of sphingolipids in mouse serum after treatment with dietary glucosylceramides. Oral administration of glucosylceramides significantly decreased SCCKN growth in the xenograft model with inhibition of angioinvasion. In tumor-invasive areas, VEGF and HIF-1α in the tumor cells, and VEGF receptor-2 in endothelial cells decreased after treatment with dietary glucosylceramides. Dietary glucosylceramides increased serum levels of sphingosine-based ceramides as compared to the control. In SCCKN and UV♀2 cells, C6-ceramide suppressed the expressions of VEGF, VEGF receptor-2, and HIF-1α in vitro. These results suggest that dietary glucosylceramides trigger the de novo pathway of ceramide synthesis, indicating that sphingosine-based ceramide suppresses the growth of head and neck tumors through the inhibition of pro-angiogenic signals such as VEGF, VEGF receptor-2, and HIF-1α.
- 1 August 2014
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (3) , 438-446
Dietary glucosylceramides suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by the inhibition of angiogenesis through an increase in ceramide
We previously reported that dietary glucosylceramides show cancer-prevention activity in a mouse xenograft model of human head and neck cancer cells (SCCKN). However, the mechanism was unclear. Ceramides, metabolites of glucosylceramides, induce apoptotic cell death in various malignancies. Here, we investigated the inhibitory effects of dietary glucosylceramides on tumor growth in vivo and in vitro. SCCKN were subcutaneously inoculated into the right flanks of NOD/SCID mice. Mice were treated with or without dietary glucosylceramides (300 mg/kg) daily for 14 consecutive days after confirmation of tumor progression. Microvessel areas around the tumor were assessed by hematoxylin–eosin staining and immunohistochemistry of CD31, and, as markers for angiogenesis, protein levels of VEGF, VEGF receptor-2, and HIF-1α were assessed by Western blotting. Mass spectrometry was performed to measure the levels of sphingolipids in mouse serum after treatment with dietary glucosylceramides. Oral administration of glucosylceramides significantly decreased SCCKN growth in the xenograft model with inhibition of angioinvasion. In tumor-invasive areas, VEGF and HIF-1α in the tumor cells, and VEGF receptor-2 in endothelial cells decreased after treatment with dietary glucosylceramides. Dietary glucosylceramides increased serum levels of sphingosine-based ceramides as compared to the control. In SCCKN and UV♀2 cells, C6-ceramide suppressed the expressions of VEGF, VEGF receptor-2, and HIF-1α in vitro. These results suggest that dietary glucosylceramides trigger the de novo pathway of ceramide synthesis, indicating that sphingosine-based ceramide suppresses the growth of head and neck tumors through the inhibition of pro-angiogenic signals such as VEGF, VEGF receptor-2, and HIF-1α.
- Open Access
- 27 January 2014
- Published by MDPI AG in Metabolites
- Vol. 4 (1) , 98-114
Comparative Analysis of Biological Sphingolipids with Glycerophospholipids and Diacylglycerol by LC-MS/MS
Liquid chromatography-electrospray ionization mass spectrometry (LC-MS) is an effective and popular technique used in lipid metabolomic studies. Although many LC-MS methods enabling the determination of sphingolipid molecular species have been reported, they do not cover a broad range of sphingolipid metabolites with expanding glycerophospholipids (GPLs) and diacylglycerol (DAG). In this study, we developed an approach for the comprehensive analysis of sphingolipids, GPLs and DAG molecular species in a biological sample, without alkaline hydrolysis. After validating the reliability of this approach, we analyzed tissue lipids of sphingomyelin synthase 2-knockout mice and found that changes in sphingolipid metabolism in the liver affect the level of docosahexaenoic acid-containing GPLs. Our method analyzes GPLs and DAG, as well as sphingolipids within biological samples and, thus, will facilitate more comprehensive studies of sphingolipid metabolism in pathology and diagnostics.
- 27 January 2014
- Published by MDPI AG in Metabolites
- Vol. 4 (1) , 98-114
Open AccessComparative Analysis of Biological Sphingolipids with Glycerophospholipids and Diacylglycerol by LC-MS/MS
Liquid chromatography-electrospray ionization mass spectrometry (LC-MS) is an effective and popular technique used in lipid metabolomic studies. Although many LC-MS methods enabling the determination of sphingolipid molecular species have been reported, they do not cover a broad range of sphingolipid metabolites with expanding glycerophospholipids (GPLs) and diacylglycerol (DAG). In this study, we developed an approach for the comprehensive analysis of sphingolipids, GPLs and DAG molecular species in a biological sample, without alkaline hydrolysis. After validating the reliability of this approach, we analyzed tissue lipids of sphingomyelin synthase 2-knockout mice and found that changes in sphingolipid metabolism in the liver affect the level of docosahexaenoic acid-containing GPLs. Our method analyzes GPLs and DAG, as well as sphingolipids within biological samples and, thus, will facilitate more comprehensive studies of sphingolipid metabolism in pathology and diagnostics.